Global Oligonucleotide Synthesis Market: Snapshot
Entry of new players in the global oligonucleotide synthesis market
has heated up competition. Players wanting to grow their market shares
have mostly resorted to cutting down prices to draw more customers. This
has also put a downward pressure on prices and subsequently many
prominent vendors have been forced to strategically cut down certain
service and product arms and focus on a niche sector.
Currently, Thermo Fisher Scientific holds
a dominant position in the global oligonucleotide synthesis market
because of its diverse product portfolio and strong outreach.
Sigma-Aldrich Corporation comes in the second position in terms of
market share.
The global oligonucleotides synthesis
market has been on a sustained growth trajectory on account of the
rapidly growing biotechnology and life sciences sectors, coupled with
the increasing uptake of the increasing applications of oligonucleotides
in research and diagnostic fields. Pharmaceutical and biotechnology
companies and research and diagnostic laboratories involved in drug
discovery and development, along with diagnostic devices and tests, for
the treatment of chronic diseases and oligonucleotides are also serving
to stoke growth in the market.
A report by Transparency Market Research
forecasts the global oligonucleotide synthesis market to expand at a
strong 11.2% CAGR from 2017 to 2025 to attain a value of US$4.189 bn by
2025 from US$1.65 bn in 2016.
Synthesized Oligonucleotides Lead Market on Account of Different Customizations Offered by Manufacturers
Depending upon the type of products, the
global oligonucleotide synthesis market can be divided into reagents and
consumables, equipment, and synthesized oligonucleotides. Among them,
the synthesized oligonucleotides segment leads the market with a
dominant share because of the increasing number of manufacturers
offering various customizations and rising applications of ready to use
synthesized oligonucleotides in therapeutics.
The two kinds of commercially used
synthesized oligonucleotide are DNA oligonucleotides and RNA
oligonucleotides. Locked Nucleic acid (LNA) and Bridged Nucleic Acid
(BNA) are the other types of synthesized oligonucleotides that find
application in research.
Presence of Numerous Small Companies Makes China Key Region in Asia Pacific
From a geographical perspective, the
global oligonucleotide synthesis market is dominated by North America.
It is expected to retain its leading share, albeit decreasing it
slightly, to account for 33.3% of the market. Strongly supporting growth
in the North America market is the growing number of pharmaceutical
companies leveraging oligonucleotides in therapeutics, research and
diagnostics. Increasing number of genetic diseases in the region and the
resultant demand for researchers to develop newer and advanced drugs to
treat them is also expected to drive the market in the region.
Europe is another key region in the
global oligonucleotide synthesis market and by 2025, it is slated to
account for 26.6% share in revenue in the market on the back of
considerable thrust on developing newer and sophisticated technologies
for building new molecules of oligonucleotides for therapeutic use.
Start-up companies with new technologies and rich patent portfolios, are
predicted to contribute to the market significantly.
In terms of growth rate, Asia Pacific
will likely surpass all other regions by clocking a healthy 12.5% CAGR
between 2017 and 2025. China is a major driver of growth in the region
on account of being home to numerous of small companies providing
reagents and consumables for oligonucleotide synthesis. Besides China,
India and Japan are also major contributors to the market because of
bettering health care infrastructure, increasing private and public
investment in life sciences research, and diagnostics advancements in
disease treatment.
Prominent participants in the global
oligonucleotide synthesis market are Thermo Fisher Scientific, GE
Healthcare, DNA Technologies, BioAutomation, Applied Biosystems,
GeneDesign, Inc., Eurofins Genomics, Integrated Kaneka Eurogentec S.A.,
Sigma-Aldrich Corporation, and Agilent Technologies.
No comments:
Post a Comment